Aura Biosciences Past Earnings Performance
Past criteria checks 0/6
Aura Biosciences's earnings have been declining at an average annual rate of -25.4%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-25.4%
Earnings growth rate
88.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -42.1% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Sep 17We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely
Sep 11We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 03Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Mar 28We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 01Aura gains as JMP starts with Bullish view citing treatment platform
Jul 19Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer
Jun 30Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Apr 10Revenue & Expenses Breakdown
How Aura Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -81 | 21 | 70 |
31 Mar 24 | 0 | -79 | 20 | 68 |
31 Dec 23 | 0 | -76 | 20 | 65 |
30 Sep 23 | 0 | -71 | 20 | 58 |
30 Jun 23 | 0 | -68 | 19 | 54 |
31 Mar 23 | 0 | -63 | 19 | 48 |
31 Dec 22 | 0 | -59 | 18 | 42 |
30 Sep 22 | 0 | -55 | 17 | 37 |
30 Jun 22 | 0 | -52 | 15 | 32 |
31 Mar 22 | 0 | -51 | 13 | 29 |
31 Dec 21 | 0 | -46 | 10 | 25 |
30 Sep 21 | 0 | -40 | 8 | 21 |
30 Jun 21 | 0 | -33 | 6 | 17 |
31 Mar 21 | 0 | -29 | 5 | 16 |
31 Dec 20 | 0 | -30 | 4 | 18 |
Quality Earnings: AURA is currently unprofitable.
Growing Profit Margin: AURA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AURA is unprofitable, and losses have increased over the past 5 years at a rate of 25.4% per year.
Accelerating Growth: Unable to compare AURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: AURA has a negative Return on Equity (-42.14%), as it is currently unprofitable.